NCT06199882暂停2 期
A Single-arm, Open, Single-center Phase II Clinical Study on the Efficacy and Safety of SBRT Sequential Surufatinib Combined With Immunotherapy for Locally Unresectable or Recurrent Biliary Tract Cancer After First Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Objective response rate(ORR)
研究概览
简要总结
This is a single-arm, open, single-center Phase II clinical study to observe and evaluate the efficacy and safety of SBRT sequential surufatinib combined with immunotherapy in patients with locally unresectable or recurrent biliary tract cancer after the first surgery.
详细描述
This is a single-arm, open, single-center Phase II clinical study to observe and evaluate the efficacy and safety of SBRT sequential surufatinib combined with immunotherapy in patients with locally unresectable or recurrent biliary tract cancer after the first surgery.The study was divided into three stages: screening period, treatment period and follow-up period. During treatment, imaging methods were used to evaluate tumor status every 6 weeks (±7 days) until disease progression (PD, RECIST 1.1) or death (during treatment) or toxicity became intolerable, and tumor treatment and survival status after disease progression were recorded. Safety outcome measures included AE, changes in laboratory test values, vital signs and electrocardiogram changes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be enrolled in this study, patients must meet all of the following criteria:
- •The subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up;
- •Age 18-75 years old (including 18 and 75 years old), gender is not limited;
- •Patients with unresectable or untreated recurrent BTC confirmed by histopathology or cytology (including intrahepatic, extrahepatic, and gallbladder cancers);
- •Have not received any anti-tumor therapy before;
- •Have at least one measurable lesion (according to RECIST 1.1 standards); Magnetic resonance imaging (MRI) enhancement or computed tomography (CT) enhancement were used to accurately measure the diameter ≥10mm, and conventional CT scan was used to measure the diameter at least 20mm.
- •Normal liver volume (total liver volume minus tumor GTV volume) exceeds 1000cc;
- •The maximum diameter of the tumor is less than 10cm, allowing up to 3 satellite foci. Satellite foci were defined as being less than 2cm and within 1cm of the gross tumor.
- •No serious organic diseases of heart, lung, brain and other organs;
- •The main organs and bone marrow functions are basically normal:
- •Blood routine: white blood cells ≥ 4.0 x 10^9/L, neutrophils ≥ 1.5 x 10^9/L, platelets ≥ 80 x 10^9/L, hemoglobin ≥ 90g/L;
- •International Standardized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5× upper limit of normal (ULN);
- •Liver function: serum total bilirubin ≤ 1.5 x ULN, ALT/AST ≤ 3 x ULN, serum total bilirubin ≤ 1.5 x ULN after internal/external drainage of obstructive jaundice;
- •Renal function: serum creatinine ≤ 1.5x ULN, creatinine clearance (CCr) ≥ 50mL/min;
- •Normal cardiac function with left ventricular ejection fraction (LVEF)≥50% as measured by two-dimensional echocardiography; Fertile male or female patients volunteered to use effective contraceptive methods, such as double barrier methods, condoms, oral or injectable contraceptives, and Iuds, during the study period and within 6 months of the last study medication. All female patients will be considered fertile unless the woman has undergone natural menopause, artificial menopause or sterilization.
排除标准
- •The study proposal shall be excluded if any of the following criteria are met:
- •Have received any antitumor therapy in the past (except simple surgical resection);
- •The tumor directly invades the stomach, small intestine or colon;
- •The maximum diameter of the lesion exceeds 10cm, or the satellite lesion does not meet the above definition criteria;
- •Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
- •There are extra-hepatic metastases (excluding local regional lymph nodes);
- •Normal liver volume is less than 1000cc;
- •The patient currently has hypertension that cannot be controlled by drugs, as follows: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg;
- •Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein volume >1.0g;
- •Patients whose tumors are judged by the investigators to be at high risk of invading vital blood vessels and causing fatal massive bleeding during the follow-up study;
- •Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months> 30 mL, hematemesis, stool, stool blood), hemoptysis (within 4 weeks > 5 mL fresh blood); Patients with a history of hereditary or acquired bleeding or coagulation disorders have clinically significant bleeding symptoms or definite bleeding tendencies within 3 months, such as gastrointestinal bleeding and hemorrhagic gastric ulcers;
- •Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; Electrocardiogram (ECG) showed QTC interval ≥480 ms.
- •Active or uncontrolled severe infection (≥CTCAE grade 2 infection);
- •Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
- •Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, in which, in the investigator's judgment, there is reason to suspect that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or that would affect the interpretation of the study results or place the patient at high risk;
- •Known human immunodeficiency virus (HIV) infection; Known history of clinically significant liver disease, including viral hepatitis [Known hepatitis B virus (HBV) carriers must rule out active HBV infection, i.e., positive HBV DNA (>1×104 copies /mL or >2000 IU/ml); known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL), or other hepatitis, cirrhosis];
- •The presence of any active, known or suspected autoimmune disease (including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, enteritis, multiple sclerosis, vasculitis, glomerulonephritis, uveitis, pituitaries, hyperthyroidism, etc.);
- •Allergy or suspected allergy to the investigational drug or similar drugs; According to the investigators' judgment, the patients had other factors that might affect the study results or lead to the forced termination of the study, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring combined treatment, serious laboratory abnormalities, and family or social factors that would affect the safety of the patients.
研究组 & 干预措施
SBRT Sequential Surufatinib Combined With Immunotherapy
Experimental
SBRT :
Bioequivalent total dose > 75Gy, completed within 2 weeks (once daily, 5 times a week).
Drug treatment (every 3 weeks is a treatment cycle) :
- Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle.
干预措施: SBRT Sequential Surufatinib Combined With Immunotherapy (Drug)
结局指标
主要结局
Objective response rate(ORR)
时间窗: up to 12 months
The proportion of subjects in the analyzed population who developed complete response (CR) and partial response (PR) according to RECIST (version 1.1) criteria.
次要结局
- Progression-free survival (PFS)(up to 12 months)
- Local control rate (LCR)(up to 12 months)
- Overall survival (OS)(up to 36 months)
- Incidence of adverse events （AE）(Until the last medication for 30 days (±7 days) or before the start of other anti-tumor therapy (whichever occurs first))
研究者
Liu luying
MD
Zhejiang Cancer Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic CancerPancreatic NeoplasmsNCT05481476Sun Yat-sen University32
尚未招募
不适用
A Study of Surufatinib in the Treatment of Advanced Soft Tissue SarcomaSoft Tissue Sarcoma AdultNCT06110650Fudan University29
已完成
2 期
Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic AdenocarcinomaPancreatic AdenocarcinomaNCT01558869The University of Hong Kong37
已完成
2 期
Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal CancerColorectal CancerNCT03146377The University of Hong Kong32
Unknown
2 期
Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX RegimenAdvanced Biliary Tract TumorsNCT04191343Zhejiang Cancer Hospital20